Abstract:Background:Immunotherapy, chemotherapy and surgery all have significant roles in the management of small-cell lung cancer (SCLC). Neoadjuvant immunotherapy combined with chemotherapy followed by surgery has shown encouraging efficacy for resectable SCLC with a good tolerability and considerable survival benefit. However, there are still few data on whether surgery for stage I-IIIA SCLC can be performed after immunotherapy with chemotherapy. Therefore, we investigated the safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgery in patients with stage I-IIIA SCLC in the hope of adding new ideas to the treatment of SCLC.Methods:The study group comprised 19 patients with stage I-IIIA SCLC who received neoadjuvant immunotherapy and chemotherapy between 2019 and 2021. Patients received 2-4 cycles of immunotherapy combined with platinum-containing dual-drug chemotherapy (platinum + paclitaxel) before surgery. Imaging evaluation was performed every two cycles until surgery. Tumor response to neoadjuvant therapy, neoadjuvant treatment related adverse events, perioperative and postoperative complications, surgical resection rate, and degree of tumor regression were evaluated. We obtained follow-up data from the patients' regular examination or treatment in hospital. If we can't complete it, contacting patients by telephone or WeChat would be adopted by us. The follow-up was not terminated until 3 months after surgery.Results:The objective response rate (ORR) was 84.2% (16/19), and no patients had progressive disease (PD). Of the 10 patients who underwent surgery, and approximately 9 (90.0%) had R0 resection. There were no perioperative deaths, and 1 case of pyothorax. The rate of pathological complete remission (pCR) and major pathological response (MPR) was 30.0% (3/10), and 40.0% (4/10) respectively. Grade 3-4 adverse reactions comprised 1 case of anemia and 1 case of constipation.Conclusions:Neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection for patients with stage I-IIIA SCLC is effective and safe with a high ORR and MPR rate, as well as a high R0 resection rate and a tolerable toxicity profile. Whether this regimen gives a survival benefit should be confirmed by further follow-up and larger, randomized controlled trials are required to confirm our findings.

Salvage extended surgery after immune-checkpoint inhibitor treatment for advanced non-small cell lung cancer

Characteristics and outcomes of salvage surgery after immune checkpoint inhibitor therapy for initially unresectable non-small cell lung cancer

Safety and Efficacy of Salvage Surgery after Treatment With Immune‐Checkpoint Adjuvant Inhibitors for Advanced Non‐Small Cell Lung Cancer: A Multicentric Study

Preliminary evaluation of immune checkpoint inhibitors as a salvage treatment of tumor recurrence after liver transplantation for hepatocellular carcinoma

Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery

Impact of salvage chemotherapy after immune checkpoint inhibitor for recurrent or metastatic head and neck cancer

Long-term Outcomes of Salvage Surgery Versus Induction Therapy Followed by Surgical Resection for Advanced NSCLC: A Propensity Score-matched Analysis

Salvage lung resection after immunotherapy is feasible and safe

Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer

Salvage surgery following tyrosine kinase inhibitor treatment for advanced non-small cell lung cancer

Salvage Surgery for Advanced Lung Adenocarcinoma after EGFR Tyrosine Kinase Inhibitor Treatment

Efficacy of Immune-checkpoint Inhibitors as the Peri-operative Treatment for Resectable Non-small-cell Lung Cancer

Predictors, surrogate, and patient-reported outcomes in immunotherapy and salvage surgery for unresectable lung cancer: a single-center retrospective study

Efficacy and Safety of Pembrolizumab Plus Chemotherapy and Sequential Surgical Resection in Initial Unresectable Stage IIIB NSCLC.

Salvage surgery following downstaging of advanced non‐small cell lung cancer by targeted therapy

[Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition]

The Role of Salvage Surgery After Definitive Radiation for Non-small-cell Lung Cancer

Salvage Surgery after Combination Immunotherapy for Initially Unresectable or Metastastic Hepatocellular Carcinoma: A Retrospective Clinical Study

Platinum‐combination chemotherapy with or without immune‐checkpoint inhibitor in patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy: A multicenter retrospective study

Safety and Effectiveness of Neoadjuvant Immunotherapy Combined with Chemotherapy Followed by Surgical Resection in Patients with Stage I-IIIA Small-Cell Lung Cancer: a Retrospective Single-Arm Clinical Trial.

Pulmonary Metastasectomy after Immune Checkpoint Inhibitors in Renal Cell Carcinoma